Immune responses of young mice to pneumococcal type 9V polysaccharide-tetanus toxoid conjugate.
Pneumococcal type 9V polysaccharide (PS), contained in the current pneumococcal vaccine, induces only a weak antibody response in young children and therefore is not an effective vaccine for young children. To increase its immunogenicity, a conjugate of PS to a protein carrier, tetanus toxoid (TT), was prepared. To quantify the immune response, mouse anti-9V PS immunoglobulin G (IgG) and IgM reference standards were established. Young mice immunized at 2 weeks of age produced IgM antibody in response to 9V PS alone or 9V PS conjugated to TT. However, only the 9V PS-TT conjugate induced an IgG antibody response and an anamnestic effect. Thus, a covalent linkage between TT and 9V PS was required for isotype switching from IgM to IgG. 9V PS-TT adsorbed with aluminum hydroxide adjuvant resulted in a fivefold or greater increase in the IgG antibody level. We also studied the effect of maternal immunization on the immune response of young mice to 9V PS-TT. Maternal immunization before mating or before mating and during gestation primed 2-week-old progeny given two injections of 9V PS-TT to produce more IgM antibody than progeny from unimmunized mothers. The IgG antibody level of neonates at birth was similar to that observed in the mothers and was probably passive antibody. These results indicate that maternal immunization with an optimum dose of a PS-protein conjugate before and/or during pregnancy, followed by immunization of the offspring with the conjugate, could provide young children with an enhanced IgM antibody response to pneumococcal PSs.
Lu
C H
CH
Department of Microbiology and Immunology, School of Medicine and Health Science, George Washington University, Washington, D.C. 20037.
Lee
C J
CJ
Kind
P
P
D000367:Age Factors; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D000917:Antibody Formation; D001428:Bacterial Vaccines / Q000276:immunology* / Q000627:therapeutic use; D005260:Female; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D008431:Maternal-Fetal Exchange; D051379:Mice; D008807:Mice, Inbred BALB C; D011008:Pneumococcal Infections / Q000517:prevention & control*; D011135:Polysaccharides, Bacterial / Q000276:immunology* / Q000627:therapeutic use; D011247:Pregnancy; D012015:Reference Standards; D013745:Tetanus Toxoid / Q000276:immunology* / Q000627:therapeutic use
D000888:Antibodies, Anti-Idiotypic; D001428:Bacterial Vaccines; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D011135:Polysaccharides, Bacterial; D013745:Tetanus Toxoid; C048844:anti-IgG; C044203:anti-IgM; C087865:pneumococcal polysaccharide type 9V